[Bide Pharmaceutical: Controlling shareholders and persons acting in concert are expected to reduce their holdings by no more than 3.01% of their shares] On September 9, Biide Pharmaceutical (688073.SH) announced that the company’s controlling shareholder and actual controller Dai Lan, Due to their own capital needs, Dai Long and persons acting in concert, Nanxu Investment and Lan Yunwanchi, plan to reduce their holdings of the company's shares through centralized bidding and block transactions from October 9, 2026 to January 8, 2027. Among them, Dai Lan plans to reduce its holdings by no more than 300,000 shares (accounting for 0.33% of the total share capital), Dai Long plans to reduce its holdings by no more than 1.559 million shares (accounting for 1.72% of the total share capital), Nanxu Investment plans to reduce its holdings by no more than 495,700 shares (accounting for 0.55% of the total share capital), and Lan Yunwanchi plans to reduce its holdings by no more than 371,800 shares (accounting for 0.41% of the total share capital). A total of no more than 2.7265 million shares are planned to be reduced, accounting for 3.01% of the total share capital.